CITIC Securities: US Tech Leads New Highs on Earnings Resilience; Q4 Focus on Four Structural Themes
CITIC Securities said in a research note that the recent global tech selloff has been driven primarily by valuation compression rather than ...
Tempus AI slides 7.63% today to $77.22 as selling pressure emerges despite bullish momentum and FDA clearance news.
Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.
AbstractIn response to the rapid evolution of generative artificial intelligence (AI), universities are being forced to take action, such as formulating guidelines. Current discussions tend to be ...
A fact I recently learnedI recently finished reading a book on automata, and according to that book, Turing machines, lambda calculus, and recursive functions all have the same computational ...
Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth rate of 23.22%. Active Companies from ...
Zcash developers released the Udon Rust crate on September 28, merging Tachyon recursive proof code into Zakura Common and ...
Anthropic and OpenAI are reportedly close to solving recursive self-improvement in AI models. Anthropic best AI model by October 2026 at 88.5% YES.
Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) extended their data license agreement through November 2029 and revised the contract's fee structure. Up to $84 million in discretionary payments ...
The revised Tempus contract extends to six years, removing Recursion Pharmaceuticals’ right to terminate for convenience. Annual payments for the third through fifth anniversaries are set at ...
15/09 Transcript : Tempus AI, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 08:30 AM 11/09 Tempus AI, Inc. lance une initiative pour constituer le plus grand ...
Oct. 07 Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug DJ Oct. 07 Tempus Expands Moderna, Merck Collaboration for Individualized Cancer Therapy MT Oct.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results